Savient sells gout med to Crealta

Share this article:

Pending court approval, Savient's orphan drug Krystexxa will join Crealta Pharmaceuticals' drug portfolio.

Savient announced the deal for its refractory chronic gout medication Wednesday.

The $120.4-million sale is part of a bankruptcy auction. The companies expect the court to weigh in on Friday.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION